Dynorphin A and related peptides administered intrathecally in the rat: A search for putative kappa opiate receptor activity

Craig Stevens, T. L. Yaksh

Research output: Contribution to journalArticle

136 Citations (Scopus)

Abstract

The intrathecal delivery of dynorphin A (1-17) and (1-13) induces, with rapid onset, a severe motor dysfunction characterized by flaccid extention of the hindlimbs and complete loss of muscle tone. This motor effect does not appear to be mediated via opiate receptors as high doses of naloxone neither block nor reverse motor dysfunction, and it is produced by dynorphin A fragments inactive at opiate receptors. At doses just below those which produce motor dysfunction, dynorphin A has no effect on nociceptive responses in the hot-plate, tail-flick and writhing tests. The selective, kappa opiate agonist, U50488H, produces a significant, dose-dependent inhibition of writhing, which is antagonized by pretreatment with naloxone, but has no effect on hot-plate and tail-flick latency. The kappa agent U50488H does not produce motor dysfunction with doses as high as 300 nmol/rat. It appears that the potent/kappa opiate activity exhibited by dynorphin A in vitro may not reflect in vivo effects of dynorphin after intrathecal administration.

Original languageEnglish
Pages (from-to)833-838
Number of pages6
JournalJournal of Pharmacology and Experimental Therapeutics
Volume238
Issue number3
StatePublished - 1 Jan 1986

Fingerprint

Dynorphins
kappa Opioid Receptor
Opioid Receptors
Opiate Alkaloids
Peptides
(trans)-Isomer 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide
Naloxone
Tail
Hindlimb
Muscles

Cite this

@article{1153fc2929c444b797412ce2669113f5,
title = "Dynorphin A and related peptides administered intrathecally in the rat: A search for putative kappa opiate receptor activity",
abstract = "The intrathecal delivery of dynorphin A (1-17) and (1-13) induces, with rapid onset, a severe motor dysfunction characterized by flaccid extention of the hindlimbs and complete loss of muscle tone. This motor effect does not appear to be mediated via opiate receptors as high doses of naloxone neither block nor reverse motor dysfunction, and it is produced by dynorphin A fragments inactive at opiate receptors. At doses just below those which produce motor dysfunction, dynorphin A has no effect on nociceptive responses in the hot-plate, tail-flick and writhing tests. The selective, kappa opiate agonist, U50488H, produces a significant, dose-dependent inhibition of writhing, which is antagonized by pretreatment with naloxone, but has no effect on hot-plate and tail-flick latency. The kappa agent U50488H does not produce motor dysfunction with doses as high as 300 nmol/rat. It appears that the potent/kappa opiate activity exhibited by dynorphin A in vitro may not reflect in vivo effects of dynorphin after intrathecal administration.",
author = "Craig Stevens and Yaksh, {T. L.}",
year = "1986",
month = "1",
day = "1",
language = "English",
volume = "238",
pages = "833--838",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Dynorphin A and related peptides administered intrathecally in the rat

T2 - A search for putative kappa opiate receptor activity

AU - Stevens, Craig

AU - Yaksh, T. L.

PY - 1986/1/1

Y1 - 1986/1/1

N2 - The intrathecal delivery of dynorphin A (1-17) and (1-13) induces, with rapid onset, a severe motor dysfunction characterized by flaccid extention of the hindlimbs and complete loss of muscle tone. This motor effect does not appear to be mediated via opiate receptors as high doses of naloxone neither block nor reverse motor dysfunction, and it is produced by dynorphin A fragments inactive at opiate receptors. At doses just below those which produce motor dysfunction, dynorphin A has no effect on nociceptive responses in the hot-plate, tail-flick and writhing tests. The selective, kappa opiate agonist, U50488H, produces a significant, dose-dependent inhibition of writhing, which is antagonized by pretreatment with naloxone, but has no effect on hot-plate and tail-flick latency. The kappa agent U50488H does not produce motor dysfunction with doses as high as 300 nmol/rat. It appears that the potent/kappa opiate activity exhibited by dynorphin A in vitro may not reflect in vivo effects of dynorphin after intrathecal administration.

AB - The intrathecal delivery of dynorphin A (1-17) and (1-13) induces, with rapid onset, a severe motor dysfunction characterized by flaccid extention of the hindlimbs and complete loss of muscle tone. This motor effect does not appear to be mediated via opiate receptors as high doses of naloxone neither block nor reverse motor dysfunction, and it is produced by dynorphin A fragments inactive at opiate receptors. At doses just below those which produce motor dysfunction, dynorphin A has no effect on nociceptive responses in the hot-plate, tail-flick and writhing tests. The selective, kappa opiate agonist, U50488H, produces a significant, dose-dependent inhibition of writhing, which is antagonized by pretreatment with naloxone, but has no effect on hot-plate and tail-flick latency. The kappa agent U50488H does not produce motor dysfunction with doses as high as 300 nmol/rat. It appears that the potent/kappa opiate activity exhibited by dynorphin A in vitro may not reflect in vivo effects of dynorphin after intrathecal administration.

UR - http://www.scopus.com/inward/record.url?scp=0022460723&partnerID=8YFLogxK

M3 - Article

C2 - 2875172

AN - SCOPUS:0022460723

VL - 238

SP - 833

EP - 838

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 3

ER -